Angle (AGL) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Oct 2022 07:00 AM
RNS
Parsortix poster presented at ISLB meeting
21 Oct 2022 06:15 PM
RNS
Issue of Equity
18 Oct 2022 07:00 AM
RNS
Streamlining of operations to increase cash runway
17 Oct 2022 02:23 PM
RNS
TR-1: Notification of major holdings
12 Oct 2022 07:00 AM
RNS
First regional distribution agreement
30 Sep 2022 05:30 PM
RNS
Holding(s) in Company
30 Sep 2022 05:30 PM
RNS
Issue of Equity
29 Sep 2022 07:00 AM
RNS
Interim Results
29 Sep 2022 07:00 AM
RNS
Positive headline results from ovarian study
28 Sep 2022 07:00 AM
RNS
Study using Parsortix in head and neck cancer
13 Sep 2022 07:00 AM
RNS
New poster presented at ASCP Meeting
12 Sep 2022 07:30 AM
RNS
Novel assay predicts malignancy in pelvic mass
01 Sep 2022 07:00 AM
RNS
Notice of Interim Results and Webcast
28 Jul 2022 07:00 AM
RNS
Novel insight into metastasis in NSCLC patients
20 Jul 2022 02:33 PM
RNS
Holding(s) in Company
20 Jul 2022 07:00 AM
RNS
NEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19 Jul 2022 10:00 AM
RNS
Director/PDMR Shareholding
15 Jul 2022 07:00 AM
RNS
Results of Capital Raise
14 Jul 2022 05:24 PM
RNS
Retail Offer via PrimaryBid
14 Jul 2022 05:23 PM
RNS
Proposed Placing and Retail Offer
08 Jul 2022 05:30 PM
RNS
Issue of Equity
29 Jun 2022 04:35 PM
RNS
Result of 2022 Annual General Meeting
27 Jun 2022 07:00 AM
RNS
Spread of breast cancer accelerates during sleep
23 Jun 2022 06:24 PM
RNS
Issue of Equity
22 Jun 2022 07:00 AM
RNS
Secured contract from pharma services customer
16 Jun 2022 07:00 AM
RNS
Predicting immunotherapy response in SCLC
14 Jun 2022 07:00 AM
RNS
Potential role of invasive cellular protrusions
30 May 2022 07:00 AM
RNS
Partnership with major United States urology group
27 May 2022 07:00 AM
RNS
Molecular characterisation of CTCs
25 May 2022 04:35 PM
RNS
Price Monitoring Extension
25 May 2022 12:30 PM
RNS
ANGLE receives FDA clearance for Parsortix
20 May 2022 07:00 AM
RNS
Prostate Cancer UK funds new study using Parsortix
28 Apr 2022 07:00 AM
RNS
Preliminary Results
20 Apr 2022 07:00 AM
RNS
Notice of Preliminary Results and Webcast
14 Apr 2022 07:00 AM
RNS
Poster on Parsortix system presented at AACR 2022
01 Apr 2022 07:00 AM
RNS
Identifying drug targets in cancer metastasis
29 Mar 2022 07:00 AM
RNS
Rapid information on patient response to therapies
25 Mar 2022 07:00 AM
RNS
Identifying therapeutic targets in TNBC patients
15 Mar 2022 07:00 AM
RNS
Update on laboratory accreditation
09 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
09 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
02 Mar 2022 06:29 PM
RNS
Holding(s) in Company
18 Feb 2022 05:13 PM
RNS
Issue of Equity
21 Jan 2022 07:00 AM
RNS
Potential in immunotherapy treatment selection
17 Jan 2022 07:00 AM
RNS
Concordance of Parsortix with tissue biopsy
13 Jan 2022 07:00 AM
RNS
Update on lab accreditation and ovarian study
10 Jan 2022 07:00 AM
RNS
Insight into drug resistance in NSCLC
22 Dec 2021 06:29 PM
RNS
Issue of Equity
01 Dec 2021 06:11 PM
RNS
Issue of Equity
01 Dec 2021 07:00 AM
RNS
Parsortix in RNA analysis of CTCs as tool in NSCLC
UK 100

Latest directors dealings